Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? 2008

Adrian F Hernandez, and Robert A Harrington
Duke Clinical Research Institute and the Division of Cardiovascular Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC 27715, USA. adrian.hernandez@duke.edu

UI MeSH Term Description Entries
D008297 Male Males
D002170 Canada The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D017257 Ramipril A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat. Acovil,Altace,Carasel,Delix,HOE-498,Ramace,Triatec,Tritace,Vesdil,Zabien,HOE 498,HOE498
D019317 Evidence-Based Medicine An approach of practicing medicine with the goal to improve and evaluate patient care. It requires the judicious integration of best research evidence with the patient's values to make decisions about medical care. This method is to help physicians make proper diagnosis, devise best testing plan, choose best treatment and methods of disease prevention, as well as develop guidelines for large groups of patients with the same disease. (from JAMA 296 (9), 2006) Medicine, Evidence-Based,Evidence Based Medicine,Medicine, Evidence Based

Related Publications

Adrian F Hernandez, and Robert A Harrington
January 1982, Annual review of pharmacology and toxicology,
Adrian F Hernandez, and Robert A Harrington
January 1994, The Journal of the American Board of Family Practice,
Adrian F Hernandez, and Robert A Harrington
January 1992, Zeitschrift fur Kardiologie,
Adrian F Hernandez, and Robert A Harrington
May 1993, The Canadian journal of cardiology,
Adrian F Hernandez, and Robert A Harrington
February 1991, Molecular and cellular neurosciences,
Adrian F Hernandez, and Robert A Harrington
January 1992, Drug safety,
Adrian F Hernandez, and Robert A Harrington
November 1994, Aviation, space, and environmental medicine,
Adrian F Hernandez, and Robert A Harrington
March 1984, Rational drug therapy,
Adrian F Hernandez, and Robert A Harrington
January 1986, Medical toxicology,
Adrian F Hernandez, and Robert A Harrington
February 1997, The British journal of dermatology,
Copied contents to your clipboard!